733 related articles for article (PubMed ID: 30150660)
1. Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors.
Miao D; Margolis CA; Vokes NI; Liu D; Taylor-Weiner A; Wankowicz SM; Adeegbe D; Keliher D; Schilling B; Tracy A; Manos M; Chau NG; Hanna GJ; Polak P; Rodig SJ; Signoretti S; Sholl LM; Engelman JA; Getz G; Jänne PA; Haddad RI; Choueiri TK; Barbie DA; Haq R; Awad MM; Schadendorf D; Hodi FS; Bellmunt J; Wong KK; Hammerman P; Van Allen EM
Nat Genet; 2018 Sep; 50(9):1271-1281. PubMed ID: 30150660
[TBL] [Abstract][Full Text] [Related]
2. Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors.
Zhang L; Han X; Shi Y
JAMA Netw Open; 2020 Aug; 3(8):e2013201. PubMed ID: 32845327
[TBL] [Abstract][Full Text] [Related]
3. Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies.
Hartmaier RJ; Charo J; Fabrizio D; Goldberg ME; Albacker LA; Pao W; Chmielecki J
Genome Med; 2017 Feb; 9(1):16. PubMed ID: 28231819
[TBL] [Abstract][Full Text] [Related]
4. Data Interoperability of Whole Exome Sequencing (WES) Based Mutational Burden Estimates from Different Laboratories.
Qiu P; Pang L; Arreaza G; Maguire M; Chang KC; Marton MJ; Levitan D
Int J Mol Sci; 2016 Apr; 17(5):. PubMed ID: 27136543
[TBL] [Abstract][Full Text] [Related]
5. Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer.
Czink E; Kloor M; Goeppert B; Fröhling S; Uhrig S; Weber TF; Meinel J; Sutter C; Weiss KH; Schirmacher P; Doeberitz MVK; Jäger D; Springfeld C
Cold Spring Harb Mol Case Stud; 2017 Sep; 3(5):. PubMed ID: 28619747
[TBL] [Abstract][Full Text] [Related]
6. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.
Chalmers ZR; Connelly CF; Fabrizio D; Gay L; Ali SM; Ennis R; Schrock A; Campbell B; Shlien A; Chmielecki J; Huang F; He Y; Sun J; Tabori U; Kennedy M; Lieber DS; Roels S; White J; Otto GA; Ross JS; Garraway L; Miller VA; Stephens PJ; Frampton GM
Genome Med; 2017 Apr; 9(1):34. PubMed ID: 28420421
[TBL] [Abstract][Full Text] [Related]
7. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD
J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779
[TBL] [Abstract][Full Text] [Related]
8. Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors.
Panda A; Betigeri A; Subramanian K; Ross JS; Pavlick DC; Ali S; Markowski P; Silk A; Kaufman HL; Lattime E; Mehnert JM; Sullivan R; Lovly CM; Sosman J; Johnson DB; Bhanot G; Ganesan S
JCO Precis Oncol; 2017; 2017():. PubMed ID: 29951597
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoints and cancer in the immunogenomics era.
Park R; Winnicki M; Liu E; Chu WM
Brief Funct Genomics; 2019 Mar; 18(2):133-139. PubMed ID: 30137232
[TBL] [Abstract][Full Text] [Related]
10. Genome-wide association analysis identifies genetic correlates of immune infiltrates in solid tumors.
Siemers NO; Holloway JL; Chang H; Chasalow SD; Ross-MacDonald PB; Voliva CF; Szustakowski JD
PLoS One; 2017; 12(7):e0179726. PubMed ID: 28749946
[TBL] [Abstract][Full Text] [Related]
11. Immune response-associated gene analysis of 1,000 cancer patients using whole-exome sequencing and gene expression profiling-Project HOPE.
Akiyama Y; Kondou R; Iizuka A; Ohshima K; Urakami K; Nagashima T; Shimoda Y; Tanabe T; Ohnami S; Ohnami S; Kusuhara M; Mochizuki T; Yamaguchi K
Biomed Res; 2016; 37(4):233-42. PubMed ID: 27544999
[TBL] [Abstract][Full Text] [Related]
12. Mutation patterns in genes encoding interferon signaling and antigen presentation: A pan-cancer survey with implications for the use of immune checkpoint inhibitors.
Budczies J; Bockmayr M; Klauschen F; Endris V; Fröhling S; Schirmacher P; Denkert C; Stenzinger A
Genes Chromosomes Cancer; 2017 Aug; 56(8):651-659. PubMed ID: 28466543
[TBL] [Abstract][Full Text] [Related]
13. The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine.
Garofalo A; Sholl L; Reardon B; Taylor-Weiner A; Amin-Mansour A; Miao D; Liu D; Oliver N; MacConaill L; Ducar M; Rojas-Rudilla V; Giannakis M; Ghazani A; Gray S; Janne P; Garber J; Joffe S; Lindeman N; Wagle N; Garraway LA; Van Allen EM
Genome Med; 2016 Jul; 8(1):79. PubMed ID: 27460824
[TBL] [Abstract][Full Text] [Related]
14. Comutations in DNA Damage Response Pathways Serve as Potential Biomarkers for Immune Checkpoint Blockade.
Wang Z; Zhao J; Wang G; Zhang F; Zhang Z; Zhang F; Zhang Y; Dong H; Zhao X; Duan J; Bai H; Tian Y; Wan R; Han M; Cao Y; Xiong L; Liu L; Wang S; Cai S; Mok TSK; Wang J
Cancer Res; 2018 Nov; 78(22):6486-6496. PubMed ID: 30171052
[TBL] [Abstract][Full Text] [Related]
15. Personalized genomic analyses for cancer mutation discovery and interpretation.
Jones S; Anagnostou V; Lytle K; Parpart-Li S; Nesselbush M; Riley DR; Shukla M; Chesnick B; Kadan M; Papp E; Galens KG; Murphy D; Zhang T; Kann L; Sausen M; Angiuoli SV; Diaz LA; Velculescu VE
Sci Transl Med; 2015 Apr; 7(283):283ra53. PubMed ID: 25877891
[TBL] [Abstract][Full Text] [Related]
16. Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis.
Snyder A; Nathanson T; Funt SA; Ahuja A; Buros Novik J; Hellmann MD; Chang E; Aksoy BA; Al-Ahmadie H; Yusko E; Vignali M; Benzeno S; Boyd M; Moran M; Iyer G; Robins HS; Mardis ER; Merghoub T; Hammerbacher J; Rosenberg JE; Bajorin DF
PLoS Med; 2017 May; 14(5):e1002309. PubMed ID: 28552987
[TBL] [Abstract][Full Text] [Related]
17. Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion.
Albacker LA; Wu J; Smith P; Warmuth M; Stephens PJ; Zhu P; Yu L; Chmielecki J
PLoS One; 2017; 12(11):e0176181. PubMed ID: 29121062
[TBL] [Abstract][Full Text] [Related]
18. Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy.
Li X; Song W; Shao C; Shi Y; Han W
Cell Mol Immunol; 2019 Jan; 16(1):28-39. PubMed ID: 30002451
[TBL] [Abstract][Full Text] [Related]
19. Integration of somatic mutation, expression and functional data reveals potential driver genes predictive of breast cancer survival.
Suo C; Hrydziuszko O; Lee D; Pramana S; Saputra D; Joshi H; Calza S; Pawitan Y
Bioinformatics; 2015 Aug; 31(16):2607-13. PubMed ID: 25810432
[TBL] [Abstract][Full Text] [Related]
20. Whole-exome sequencing reveals recurrent somatic mutation networks in cancer.
Liu X; Wang J; Chen L
Cancer Lett; 2013 Nov; 340(2):270-6. PubMed ID: 23153794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
